MBP Milk Basic Protein.

Milk basic protein acts on the osteoblast and osteoclast side of bone turnover rather than supplying mineral. Calcium provides the mineral those cells deposit, so the two cover separate halves of bone maintenance.

Calcitriol drives intestinal calcium absorption through calbindin and TRPV6, setting how much calcium reaches circulation. Without adequate vitamin D status the mineral side of an MBP formula is limited before bone cells are ever reached.

MK-7 is the cofactor for gamma-carboxylation of osteocalcin, the osteoblast protein that binds calcium into the matrix. MBP works on osteoblast activity, and K2 determines whether the protein those cells release can bind mineral.

About half of body magnesium sits in bone, where it influences hydroxyapatite crystal size, and it is also needed for the hydroxylases that activate vitamin D. It is a standing companion to any calcium-plus-bone-cell formula.

Type I collagen is the organic scaffold that bone mineral is laid down on. Collagen peptides supply matrix amino acids while MBP acts on the cells that build and remodel that scaffold.

Strontium is chemically close to calcium and substitutes for it in hydroxyapatite and at the intestinal absorption step. In a shared formula the two compete for uptake, so they are usually separated in time.

Lactoferrin is one of the cationic whey proteins present in the milk basic protein fraction, and it is the component most often named when the fraction's action on bone cells is discussed. Adding isolated lactoferrin therefore raises the dose of something already inside the fraction rather than adding a new mechanism. Count it once when totalling.

Lactoferrin binds ferric iron with high affinity, which is its defining biochemical property. Taken in the same dose as an iron supplement, an iron-binding protein changes the chemical form the intestine sees. Whether that raises or lowers uptake depends on the receptor route involved, so the practical handling is to separate the two rather than assume a direction.

Ascorbate is the cofactor for prolyl and lysyl hydroxylase, the enzymes that hydroxylate collagen chains before cross-linking. Type I collagen is the organic scaffold that bone mineral deposits onto. A protein fraction acting on bone cells does not remove the need for that cofactor.

Lysine residues are the substrate for lysyl hydroxylase and lysyl oxidase, the steps that create collagen cross-links, and lysine is also a required amino acid supplied by diet. Collagen synthesis in bone matrix depends on that residue being available. This is precursor supply, not an effect on bone cells.

Proline and its hydroxylated form make up a large share of collagen's residues, which is why proline availability sits upstream of matrix formation. Bone's organic phase is mostly type I collagen. The role is substrate supply for the scaffold.

Lysyl oxidase is a copper-dependent enzyme and it performs the cross-linking that gives collagen its tensile strength. Without copper the matrix forms but cross-links poorly. This is a settled cofactor requirement in bone matrix biology.

Zinc is a cofactor for alkaline phosphatase, the osteoblast enzyme used as a bone formation marker, and for collagenase family enzymes involved in matrix turnover. Osteoblast activity depends on zinc status. Alkaline phosphatase is a marker of that activity rather than an outcome.

Manganese is a cofactor for glycosyltransferases that build the glycosaminoglycan and proteoglycan components of connective tissue matrix. Those components sit alongside collagen in bone's organic phase. The requirement is established; the amount that matters in a supplement context is less well defined.

Boron has been described as affecting urinary calcium and magnesium excretion and steroid hormone metabolism in controlled feeding work. Those are markers of mineral handling, not measures of bone strength. It is a different lever from a protein fraction acting on bone cells, which is the reason to note the pair.

Orthosilicic acid has been described as supporting collagen type I synthesis and matrix mineralisation in bone cell work. That is cell-level evidence about the matrix side. It complements rather than duplicates a cationic protein fraction.

Vitamin K is the cofactor for gamma-glutamyl carboxylase, which carboxylates osteocalcin so it can bind calcium in bone matrix. Undercarboxylated osteocalcin is a marker of insufficient vitamin K for that step. Menaquinone forms have longer circulating half-lives than phylloquinone, which is a pharmacokinetic difference between the forms and not a ranking of them.

Alkaline potassium salts buffer dietary acid load, and acid load is associated with higher urinary calcium excretion. Reducing that excretion is a handling effect measured in urine. The association with bone endpoints is an association and not a demonstrated bone effect.

Fermentable fructans lower colonic pH through short-chain fatty acid production, which increases the soluble calcium fraction available for paracellular absorption in the large intestine. That mechanism has been described in mineral balance work. It acts on calcium uptake, a different step from what a bone-cell-active protein does.

Milk basic protein is a cationic minor fraction separated from whey, so a whey isolate is the same starting material with the basic fraction present only in trace amounts. A trial of whey protein supplementation in adults with excess body weight did not detect an effect on bone quantity, which is a failure to detect rather than evidence of no effect, and it does not transfer to the isolated basic fraction either way. Pairing them means overlapping protein intake, not a doubled dose of the basic fraction.

Whey-derived protein isolates carry only residual lactose, but people who react to small amounts sometimes pair a dairy protein with lactase. The enzyme addresses the carbohydrate, not the protein. It is a tolerance measure rather than a mechanistic synergy.

Calcium supplies the mineral phase while a bone-cell-active protein fraction acts on the cells that lay it down, so the two work at different points and were studied against different endpoints. Carbonate needs stomach acid to dissolve and is taken with food for that reason. This describes distinct roles rather than an enhancement of either.